These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 33556416)

  • 1. Utilisation of parametric methods to improve percentile-based estimates for the carcinogenic potency of nitrosamines.
    Thomas R; Thresher A; Ponting DJ
    Regul Toxicol Pharmacol; 2021 Apr; 121():104875. PubMed ID: 33556416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data.
    Thresher A; Foster R; Ponting DJ; Stalford SA; Tennant RE; Thomas R
    Regul Toxicol Pharmacol; 2020 Oct; 116():104749. PubMed ID: 32777431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA).
    Kruhlak NL; Schmidt M; Froetschl R; Graber S; Haas B; Horne I; Horne S; King ST; Koval IA; Kumaran G; Langenkamp A; McGovern TJ; Peryea T; Sanh A; Siqueira Ferreira A; van Aerts L; Vespa A; Whomsley R
    Regul Toxicol Pharmacol; 2024 Jun; 150():105640. PubMed ID: 38754805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comprehensive prediction of carcinogenic potency and tumorigenic dose (TD
    Frydrych A; Jurowski K
    Chem Biol Interact; 2024 Feb; 389():110864. PubMed ID: 38199258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acceptable intakes (AIs) for 11 small molecule N-nitrosamines (NAs).
    Bercu JP; Masuda-Herrera M; Trejo-Martin A; Sura P; Jolly R; Kenyon M; Thomas R; Ponting DJ; Snodin D; Tuschl G; Simon S; De Vlieger K; Hutchinson R; Czich A; Glowienke S; Reddy MV; Johanssen S; Vock E; Claude N; Weaver RJ
    Regul Toxicol Pharmacol; 2023 Aug; 142():105415. PubMed ID: 37257751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Kinetic Model for Assessing Potential Nitrosamine Carcinogenicity.
    Yu S; McWilliams JC; Dirat O; Dobo KL; Kalgutkar AS; Kenyon MO; Martin MT; Watt ED; Schuler M
    Chem Res Toxicol; 2024 Aug; 37(8):1382-1393. PubMed ID: 39075630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of the TD50 99 % CI for single dose rodent carcinogenicity studies.
    Thomas R; Oliveira AAF; Ponting DJ; Thresher A
    Toxicol Lett; 2023 Dec; 390():1-4. PubMed ID: 37923025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of Nitrosamine Mutagenicity and Their Relationship to Rodent Carcinogenic Potency.
    Snodin DJ; Trejo-Martin A; Ponting DJ; Smith GF; Czich A; Cross K; Custer L; Elloway J; Greene N; Kalgutkar AS; Stalford SA; Tennant RE; Vock E; Zalewski A; Ziegler V; Dobo KL
    Chem Res Toxicol; 2024 Feb; 37(2):181-198. PubMed ID: 38316048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-nitrosamine impurity risk assessment in pharmaceuticals: Utilizing In vivo mutation relative potency comparison to establish an acceptable intake for NTTP.
    Powley MW; Sobol Z; Johnson GE; Clark RW; Dalby SM; Ykoruk BA; Galijatovic-Idrizbegovic A; Mowery MD; Escobar PA
    Regul Toxicol Pharmacol; 2024 Sep; 152():105681. PubMed ID: 39067806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative correlation of carcinogenic potency with four different classes of short-term test data.
    Travis CC; Wang LA; Waehner MJ
    Mutagenesis; 1991 Sep; 6(5):353-60. PubMed ID: 1795638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Setting limits for N-nitrosamines in drugs: A defined approach based on read-across and structure-activity relationship for N-nitrosopiperazine impurities.
    Dos Santos CEM; Dorta DJ; de Oliveira DP
    Regul Toxicol Pharmacol; 2022 Dec; 136():105288. PubMed ID: 36384172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing Structure-Activity Relationships for
    Cross KP; Ponting DJ
    Comput Toxicol; 2021 Nov; 20():. PubMed ID: 34901581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. METASTATIC NODULAR MELANOMA DEVELOPING ON NEVUS SPILUS DURING INTAKE OF BETA BLOCKERS (BISOPROLOL/NEBIVOLOL) AND ACE INHIBITORS (PERINDOPRIL). POTENTIAL LINKS TО THE DRUG RELATED NITROSOGENESIS/CARCINOGENESIS, DUNNING-KRUGER EFFECT AND GENETIC WEAPONS OF THE NEW GENERATION.
    Tchernev G
    Georgian Med News; 2023 Oct; (343):172-178. PubMed ID: 38096536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantum Mechanical Assessment of Nitrosamine Potency.
    De S; Thapa B; Sayyed FB; Frank SA; Cornwell PD; Jolly RA
    Chem Res Toxicol; 2024 Jun; 37(6):1011-1022. PubMed ID: 38804898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the correlation coefficient between the TD50 and the MTD.
    Razzaghi M; Gaylor DW
    Risk Anal; 1996 Feb; 16(1):107-13. PubMed ID: 8868225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uncertainty in cancer risk estimates.
    Gaylor DW; Chen JJ; Sheehan DM
    Risk Anal; 1993 Apr; 13(2):149-54. PubMed ID: 8502788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutagenic impurities in pharmaceuticals: A critical assessment of the cohort of concern with a focus on N-nitrosamines.
    Snodin DJ
    Regul Toxicol Pharmacol; 2023 Jun; 141():105403. PubMed ID: 37116739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational Prediction of Metabolic α-Carbon Hydroxylation Potential of
    Chakravarti S
    Chem Res Toxicol; 2023 Jun; 36(6):959-970. PubMed ID: 37267457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian derivation of an oral cancer slope factor distribution for 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK).
    Naufal Z; Kathman S; Wilson C
    Regul Toxicol Pharmacol; 2009 Oct; 55(1):69-75. PubMed ID: 19505520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Permitted daily exposure limits for noteworthy N-nitrosamines.
    Johnson GE; Dobo K; Gollapudi B; Harvey J; Kenny J; Kenyon M; Lynch A; Minocherhomji S; Nicolette J; Thybaud V; Wheeldon R; Zeller A
    Environ Mol Mutagen; 2021 Jun; 62(5):293-305. PubMed ID: 34089278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.